X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1074) 1074
Publication (62) 62
Book Chapter (20) 20
Conference Proceeding (4) 4
Book Review (3) 3
Paper (3) 3
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
thienopyridines (544) 544
humans (449) 449
index medicus (381) 381
thienopyridine (364) 364
clopidogrel (350) 350
male (240) 240
aspirin (218) 218
prasugrel (208) 208
ticlopidine - analogs & derivatives (203) 203
animals (168) 168
female (167) 167
platelet aggregation inhibitors - therapeutic use (166) 166
pharmacology & pharmacy (158) 158
percutaneous coronary intervention (152) 152
cardiac & cardiovascular systems (148) 148
platelet aggregation inhibitors - pharmacology (130) 130
middle aged (128) 128
antiplatelet therapy (124) 124
acute coronary syndromes (117) 117
prasugrel hydrochloride (116) 116
platelet aggregation inhibitors - adverse effects (115) 115
chemistry, organic (109) 109
aged (108) 108
ticlopidine - therapeutic use (96) 96
platelet aggregation inhibitors - administration & dosage (93) 93
thrombosis (93) 93
peripheral vascular disease (92) 92
acute coronary syndrome (88) 88
hematology (85) 85
ticagrelor (84) 84
myocardial-infarction (82) 82
platelet aggregation - drug effects (81) 81
risk factors (75) 75
platelets (74) 74
aspirin - therapeutic use (73) 73
rats (71) 71
treatment outcome (71) 71
adult (70) 70
thiophenes - pharmacology (70) 70
ticlopidine (69) 69
ticlopidine - adverse effects (66) 66
ticlopidine - pharmacology (66) 66
derivatives (64) 64
ticlopidine - administration & dosage (64) 64
blood platelets - drug effects (61) 61
drug therapy, combination (61) 61
active metabolite (59) 59
azepines - pharmacology (59) 59
p2y (59) 59
piperazines - pharmacology (59) 59
chemistry, multidisciplinary (58) 58
aggregation (54) 54
platelet aggregation (53) 53
platelet aggregation inhibitors - pharmacokinetics (53) 53
blood platelets (52) 52
pyridine (51) 51
therapy (51) 51
drug therapy (50) 50
chemistry, medicinal (49) 49
inhibitors (49) 49
acute coronary syndrome - drug therapy (48) 48
chemistry (48) 48
pharmacokinetics (48) 48
pyridines - pharmacology (48) 48
antiplatelet (47) 47
dose-response relationship, drug (47) 47
platelet activating factor - antagonists & inhibitors (47) 47
time factors (47) 47
chemistry, inorganic & nuclear (46) 46
coronary heart disease (46) 46
stents (46) 46
aspirin - administration & dosage (45) 45
piperazines - pharmacokinetics (45) 45
analysis (44) 44
drug interactions (44) 44
thienopyridines - therapeutic use (44) 44
thiophenes - therapeutic use (44) 44
cardiovascular (43) 43
molecular structure (43) 43
piperazines - therapeutic use (43) 43
thiophenes - pharmacokinetics (43) 43
triazoles - pharmacology (43) 43
abridged index medicus (42) 42
adp (42) 42
inhibition (42) 42
purinergic p2 receptor antagonists (42) 42
stent thrombosis (42) 42
thienopyridines - pharmacology (42) 42
care and treatment (41) 41
proton pump inhibitors (40) 40
trial (40) 40
st-segment elevation (39) 39
platelet (38) 38
acute myocardial-infarction (37) 37
aspirin - adverse effects (37) 37
blood platelets - metabolism (37) 37
cangrelor (37) 37
hemorrhage - chemically induced (37) 37
intervention (37) 37
cardiac patients (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1026) 1026
German (18) 18
French (15) 15
Spanish (9) 9
Russian (8) 8
Japanese (5) 5
Korean (4) 4
Chinese (3) 3
Croatian (2) 2
Polish (2) 2
Danish (1) 1
Hungarian (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOVASCULAR EVENTS | TRANSIENT ISCHEMIC ATTACK | ACID SUPPRESSION | ACUTE CORONARY SYNDROMES | H-2-RECEPTOR ANTAGONISTS | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
The American Journal of Gastroenterology, ISSN 0002-9270, 12/2010, Volume 105, Issue 12, pp. 2533 - 2549
This expert consensus document was developed by the American College of Cardiology Foundation (ACCF), the American College of Gastroenterology (ACG), and the... 
proton pump inhibitors | aspirin | ACCF Expert Consensus Document antiplatelet drugs | gastrointestinal hemorrhage | thienopyridine | platelet aggregation inhibitors | CARDIOVASCULAR EVENTS | TRANSIENT ISCHEMIC ATTACK | ACID SUPPRESSION | ACUTE CORONARY SYNDROMES | H-2-RECEPTOR ANTAGONISTS | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACUTE MYOCARDIAL-INFARCTION | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | GASTROENTEROLOGY & HEPATOLOGY | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 11/2014, Volume 22, Issue 21, pp. 5860 - 5870
To identify new potent multidrug resistance modulators, we have synthesized a series of novel thieno[2,3- ]pyridines and furo[2,3- ]pyridines, and examined... 
P-glycoprotein | Thieno[2,3-b]pyridine | Multidrug resistance-associated protein | Multidrug resistance modulators | Breast cancer resistance protein | BCRP | DESIGN | ABC | CHEMISTRY, MEDICINAL | PROTEIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | THIENOPYRIDINE | CHEMISTRY, ORGANIC | REVERSAL | AGENTS | INHIBITORS | DERIVATIVES | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | NIH 3T3 Cells | Calcium Channels - metabolism | Calcium - metabolism | Drug Resistance, Multiple - drug effects | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Thienopyridines - metabolism | Neoplasm Proteins - antagonists & inhibitors | Structure-Activity Relationship | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Neoplasm Proteins - metabolism | Thienopyridines - pharmacology | ATP-Binding Cassette Transporters - metabolism | Calcium Channel Blockers - metabolism | Thienopyridines - chemistry | Cell Line | Cell Survival - drug effects | Rats | Multidrug Resistance-Associated Proteins - antagonists & inhibitors | Thienopyridines - toxicity | Muscle, Smooth - metabolism | Calcium Channel Blockers - toxicity | Animals | Calcium Channels - chemistry | Calcium Channel Blockers - chemistry | Protein Binding | Mice | Multidrug Resistance-Associated Proteins - metabolism | ATP-Binding Cassette Transporters - antagonists & inhibitors | Drug resistance in microorganisms | Pyridine
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e89S - e119S
The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics of aspirin, dipyridamole, cilostazol, the thienopyridines, and the... 
HIGH-RISK PATIENTS | GLYCOPROTEIN IIB/IIIA INHIBITORS | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | RESPIRATORY SYSTEM | FIBRINOGEN RECEPTOR ANTAGONISTS | TRANSIENT ISCHEMIC ATTACK | ACUTE MYOCARDIAL-INFARCTION | PLACEBO-CONTROLLED TRIALS | DOUBLE-BLIND | ACUTE CORONARY SYNDROMES | CRITICAL CARE MEDICINE | Dipyridamole - pharmacokinetics | United States | Humans | Thienopyridines - adverse effects | Aspirin - pharmacokinetics | Dose-Response Relationship, Drug | Societies, Medical | Aspirin - adverse effects | Dipyridamole - adverse effects | Aspirin - therapeutic use | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Thrombosis - blood | Thrombosis - prevention & control | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Evidence-Based Medicine | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Randomized Controlled Trials as Topic | Thienopyridines - pharmacokinetics | Thienopyridines - therapeutic use | Tetrazoles - therapeutic use | Platelet Activation - drug effects | Thrombosis - drug therapy | Tetrazoles - adverse effects | Tetrazoles - pharmacokinetics | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Journal Article
Journal of Drug Delivery Science and Technology, ISSN 1773-2247, 06/2017, Volume 39, p. 490
Journal Article
Drugs, ISSN 0012-6667, 12/2012, Volume 72, Issue 16, pp. 2087 - 2116
Our knowledge of the mechanisms of platelet-mediated thrombosis has increased dramatically over the last 40 years. This increased understanding has identified... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Cangrelor | ONO-3708 | Eptifibatide | Tirofiban | Vorapaxar | Sulotroban | Terutroban-sodium | Ramatroban | Ticagrelor | Atopaxar | Vapiprost | Aspirin | Abciximab | Pantoprazole | Picotamide | Thienopyridines | Cilostazol | Pharmacology | Z-335 | Egaptivon-pegol | Sarpogrelate | Ticlopidine | Omeprazole | Prasugrel | Elinogrel | Antiplatelets | Clopidogrel | Ifetroban | Pharmacokinetics | Acute-coronary-syndromes | MAINTENANCE-DOSE CLOPIDOGREL | GLYCOPROTEIN IIB/IIIA INHIBITORS | TIMI 38 TRIAL | RECURRENT CARDIOVASCULAR EVENTS | ASSOCIATION TASK-FORCE | PHARMACOLOGY & PHARMACY | TREATMENT PLATELET REACTIVITY | TOXICOLOGY | THROMBOTIC THROMBOCYTOPENIC PURPURA | P2Y RECEPTOR BLOCKADE | ELEVATION MYOCARDIAL-INFARCTION | ACCF/AHA FOCUSED UPDATE | Acute Coronary Syndrome - drug therapy | Purinergic P2Y Receptor Antagonists - pharmacology | Thienopyridines - pharmacokinetics | Thienopyridines - pharmacology | Humans | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Aspirin - pharmacokinetics | Platelet Aggregation Inhibitors - pharmacology | Platelet Aggregation Inhibitors - pharmacokinetics | Aspirin - pharmacology | Blood Platelets - drug effects | Aggregation | Blood platelets | Patient outcomes | Dosage and administration | Diagnosis | Drug therapy | Coronary heart disease | Health aspects
Journal Article
European Heart Journal, ISSN 0195-668X, 8/2009, Volume 30, Issue 16, pp. 1964 - 1977
Currently, clopidogrel is recommended for treatment of patients with acute coronary syndrome and/or percutaneous coronary intervention. However, the delayed... 
Prasugrel | Clopidogrel | Thienopyridine | Cangrelor | Ticagrelor | Purinoceptor P2Y
Journal Article
Journal Article